CG
RDHL

Cutler Group’s Redhill Biopharma RDHL Stock Holding History

Cutler Group’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6
Closed -$17K – 5898
2021
Q4 		$17K Sell
6
-2
-25% -$8K ﹤0.01% 3260
2021
Q3 		$16K Buy
+8
New +$54.3K ﹤0.01% 3546
2020
Q3 		– Sell
-1
Closed -$1K – 5150
2020
Q2 		$1K Hold
1
– – ﹤0.01% 4126
2020
Q1 		$2K Buy
+1
New +$5K ﹤0.01% 3538

Other funds holding RDHL

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $837M AUM 25.51% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Cutler Group's RDHL Position: Q2 2022 in Review

Cutler Group held its Redhill Biopharma (RDHL) position steady in Q2 2022 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5538.

Cutler Group first reported a position in RDHL in Q3 2019 and has held it in 7 quarters since. The position peaked at $17K in Q3 2021. 44 funds tracked by Wall St. Rank hold RDHL as of Q2 2022.

  • Cutler Group held 0 shares of Redhill Biopharma worth $0 as of Q2 2022.
  • Cutler Group left its Redhill Biopharma share count unchanged in Q2 2022.
  • Redhill Biopharma made up ﹤0.01% of Cutler Group's portfolio in Q2 2022, its #5538 holding.
  • Cutler Group first reported a position in Redhill Biopharma in Q3 2019 and has held it in 7 quarters since.
  • Cutler Group's Redhill Biopharma position peaked at $17K in Q3 2021.
  • 44 funds tracked by Wall St. Rank held Redhill Biopharma as of Q2 2022.

Based on Cutler Group's 13F filing for Q2 2022, filed 4 Aug 2022.